SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Haemonetics Corp. – ‘8-K’ for 8/10/22

On:  Wednesday, 8/10/22, at 6:06am ET   ·   For:  8/10/22   ·   Accession #:  313143-22-50   ·   File #:  1-14041

Previous ‘8-K’:  ‘8-K’ on 8/8/22 for 8/5/22   ·   Latest ‘8-K’:  This Filing

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 8/10/22  Haemonetics Corp.                 8-K:2,9     8/10/22   11:1M

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     36K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML    278K 
 6: R1          Document and Entity Information                     HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- hae-20220810_htm                    XML     21K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- hae-20220810_lab                      XML     67K 
 5: EX-101.PRE  XBRL Presentations -- hae-20220810_pre               XML     33K 
 3: EX-101.SCH  XBRL Schema -- hae-20220810                          XSD     10K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
11: ZIP         XBRL Zipped Folder -- 0000313143-22-000050-xbrl      Zip     38K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C: 
  hae-20220810  
 i 0000313143 i false00003131432022-08-102022-08-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM  i 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)  i August 10, 2022

 i HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
 i Massachusetts i 001-14041 i 04-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

 i 125 Summer Street
 i Boston,  i MA  i 02110
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code  i 781- i 848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 i Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 i Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 i Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 i Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
 i Common stock, $.01 par value per share i HAE i New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
  i 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.





Item 2.02 Results of Operations and Financial Condition. 
On August 10, 2022, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended July 2, 2022. A copy of the press release is furnished with this report as Exhibit 99.1.
 
The foregoing information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit NumberDescription
Press Release of Haemonetics Corporation dated August 10, 2022 announcing financial results for the first quarter ended July 2, 2022.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
By:/s/ Christopher A. Simon
Name:Christopher A. Simon
Title:President and Chief Executive Officer



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:8/10/2210-Q
7/2/2210-Q
 List all Filings 
Top
Filing Submission 0000313143-22-000050   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Sep. 26, 1:50:04.1am ET